BC Innovations | Jun 28, 2019
Product Development

How Array stayed alive long enough to grow up

Array’s 21-year journey as an independent platform company, culminating in an $11.4 billion buyout, required shifting focus from research to development and back again. The acquisition sends a message that developing focused expertise and sticking...
BC Extra | Jun 17, 2019
Company News

Array takeout buoys biotechs, strengthens Pfizer in targeted oncology

Public biotechs got a boost Monday on the strength of Pfizer's $11.4 billion buyout of Array, signaling that continued M&A interest in the sector can help reverse the loss in momentum that has led to...
BC Extra | Mar 1, 2019
Company News

Ex-Merck China R&D head joins Ascletis as CMO

Antiviral and cancer company Ascletis Pharma Inc. (HKSE:1672) hired Zhengqing Li as CMO and president of R&D Greater China. He was global VP of MSD China and general manager of the Merck & Co. Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Nov 30, 2018
Company News

Ascletis adds HBV therapy to portfolio through Roche partnership

With one marketed HCV therapy in China and another under review, Ascletis Pharma Inc. (HKSE:1672) extended its commercial viral hepatitis footprint in the country on Nov. 20 with exclusive rights to marketed HBV drug Pegasys...
BC Extra | Nov 20, 2018
Company News

Ascletis adds marketed HBV drug from Roche to Chinese portfolio

With one marketed HCV therapy in China and another under review, Ascletis Pharma Inc. (HKSE:1672) extended its commercial viral hepatitis footprint in the country on Tuesday with exclusive rights to marketed HBV drug Pegasys peginterferon...
BC Extra | Aug 31, 2018
Financial News

Ascletis gains after reporting interim revenues

After weeks of getting hammered against the backdrop of a vaccine scandal and trade war that's weighed generally on Chinese stocks, Ascletis Pharma Inc. (HKSE:1672) gained HK$2.02 (28%) to HK$9.24 on Friday. The move coincides...
BioCentury | Aug 4, 2018
Finance

Hong Kong’s first wave

Having broken the seal on the new biotech chapter of Hong Kong Exchange and Clearing Ltd., the performance of Ascletis Pharma Inc. and the next few companies to go out could determine what happens to...
BC Week In Review | Aug 3, 2018
Clinical News

Ascletis' NDA for second HCV therapy accepted in China, company begins trading in Hong Kong

Ascletis Pharma Inc. (HKSE:1672) said China's State Drug Administration accepted its NDA for HCV therapy ravidasvir, a second-generation HCV NS5A protein inhibitor. In June, Ascletis launched HCV drug Ganovo danoprevir in China. Ascletis has rights...
BC Extra | Aug 3, 2018
Financial News

Ascletis ends first trading week on downturn

Ascletis Pharma Inc. (HKSE:1672) sank HK$1.84 (16%) to HK$10.02 on Friday, ending its first week of trading down 28% from its IPO price of HK$14. This week, Ascletis became the first biotech to go public...
Items per page:
1 - 10 of 141